Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamli N W Faour

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Arthroplasty Today|August 14, 2025
Fewer Pills for Fewer Problems: Strategies for Reducing Postoperative Opioid Prescribing Following Total Joint ArthroplastyCatherine M Call, Mary Noyes, Kamli N W Faour, et al.
The Journal of Arthroplasty|February 4, 2026
Quantifying Clinical Encounters for Orthopaedic Hip and Knee Surgeries: A Retrospective Analysis of Provider WorkloadAdam J Rana, Janel K Sewell, Amanda V Sirisoma, et al.
Arthroplasty Today|July 4, 2025
Toward Opioid-Free Total Hip Arthroplasty: A Retrospective Study of a Targeted Opioid Reduction Program in 229 PatientsMary L Noyes, Kamli N W Faour, Zoë A Walsh, et al.
Nature|July 12, 2023
A framework for individualized splice-switching oligonucleotide therapyJinkuk Kim, Sijae Woo, Claudio M de Gusmao, et al.
Nature Medicine|April 14, 2026
Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathyTojo Nakayama, Christelle M El Achkar, Lisseth E Burbano, et al.
Medrxiv : the Preprint Server for Health Sciences|October 9, 2023
Heterozygous loss-of-function <i>SMC3</i> variants are associated with variable and incompletely penetrant growth and developmental featuresMorad Ansari, Kamli N W Faour, Akiko Shimamura, et al.
HGG Advances|February 1, 2024
Heterozygous loss-of-function SMC3 variants are associated with variable growth and developmental featuresMorad Ansari, Kamli N W Faour, Akiko Shimamura, et al.
Medrxiv : the Preprint Server for Health Sciences|March 11, 2026
Clinical, <i>in vitro,</i> and <i>in vivo</i> evidence of <i>WAPL</i> as a novel cohesinopathy gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
American Journal of Human Genetics|July 10, 2026
Clinical, in vitro, and in vivo evidence of WAPL as a cohesinopathy-associated gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Arthroplasty Today|August 14, 2025
Fewer Pills for Fewer Problems: Strategies for Reducing Postoperative Opioid Prescribing Following Total Joint ArthroplastyCatherine M Call, Mary Noyes, Kamli N W Faour, et al.
The Journal of Arthroplasty|February 4, 2026
Quantifying Clinical Encounters for Orthopaedic Hip and Knee Surgeries: A Retrospective Analysis of Provider WorkloadAdam J Rana, Janel K Sewell, Amanda V Sirisoma, et al.
Arthroplasty Today|July 4, 2025
Toward Opioid-Free Total Hip Arthroplasty: A Retrospective Study of a Targeted Opioid Reduction Program in 229 PatientsMary L Noyes, Kamli N W Faour, Zoë A Walsh, et al.
Nature|July 12, 2023
A framework for individualized splice-switching oligonucleotide therapyJinkuk Kim, Sijae Woo, Claudio M de Gusmao, et al.
Nature Medicine|April 14, 2026
Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathyTojo Nakayama, Christelle M El Achkar, Lisseth E Burbano, et al.
Medrxiv : the Preprint Server for Health Sciences|October 9, 2023
Heterozygous loss-of-function <i>SMC3</i> variants are associated with variable and incompletely penetrant growth and developmental featuresMorad Ansari, Kamli N W Faour, Akiko Shimamura, et al.
HGG Advances|February 1, 2024
Heterozygous loss-of-function SMC3 variants are associated with variable growth and developmental featuresMorad Ansari, Kamli N W Faour, Akiko Shimamura, et al.
Medrxiv : the Preprint Server for Health Sciences|March 11, 2026
Clinical, <i>in vitro,</i> and <i>in vivo</i> evidence of <i>WAPL</i> as a novel cohesinopathy gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
American Journal of Human Genetics|July 10, 2026
Clinical, in vitro, and in vivo evidence of WAPL as a cohesinopathy-associated gene and phenotypic driver of 10q22.3q23.2 genomic disorderPhilip M Boone, Serkan Erdin, Abucar Mohamed, et al.
Pageof 1